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Introduction
Mechanical ventilation (MV) is one of the most fre-
quently used forms of supportive therapy in the ICU [1]. 
It is currently employed in the ICU management of a 
wide variety of conditions leading to respiratory failure as 
well as other life threatening pathologies such as stroke, 
cardiac failure, postoperative illness and others. Although 
it is life-saving in ICU patients, MV is also associated 
with numerous potential complications. Indeed, MV can 
be associated with lung injury, the severity of which 
depends on the levels of alveolar stress and strain as well 
as the inherent susceptibility of a previously damaged 
lung [2,3]. Th   is phenomenon is called ventilator-induced 
lung injury (VILI) [4], and research initially performed in 
animal models led to the important discovery that VILI 
can be mitigated and clinical outcomes in patients with 
lung injury improved by ventilating lungs with limited 
pressure and/or low tidal volume (so-called protective 
ventilation) [5-7].
In the 1980s and early 1990s, there was a frequently 
held view among intensivists that many patients who 
developed ventilatory failure when faced with an in-
creased work of breathing were suﬀ  ering from a state of 
diaphragmatic fatigue. Th   is led to the belief that a period 
of ‘diaphragmatic rest’, achieved through the use of 
controlled MV to completely suppress diaphragmatic 
activity, might be a useful measure. Th  is idea has now 
been completely turned on its head with the demon-
stration that controlled MV is associated with adverse 
aﬀ  ects on multiple aspects of diaphragmatic structure 
and function. Th   is condition, which was initially termed 
ventilator-induced diaphragmatic dysfunction (VIDD) by 
Vassilakopoulos and Petrof [8], appears to aﬀ  ect other 
respiratory muscles as well as the diaphragm [9,10], and 
has important implications for how patients undergoing 
MV should be managed.
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© 2011 BioMed Central LtdTh   e purpose of this article is to brieﬂ  y outline the key 
data that have unequivocally demonstrated the adverse 
eﬀ  ects of controlled MV on the diaphragm in animal 
models. We will then turn our major focus to several very 
recently published human studies [11-15] that have 
largely conﬁ  rmed the observations about VIDD made in 
the animal studies. Finally, we will oﬀ  er some clinical as 
well as future research perspectives on the problem of 
VIDD in ICU patients.
Brief review of animal model data
For the purposes of this review, VIDD refers to MV-
induced changes in diaphragmatic function that arise 
from alterations outside of the central or peripheral 
nervous systems. Indeed, in animal models of VIDD the 
contractility of isolated diaphragmatic strips is severely 
reduced despite normal nervous impulse transmission 
and neuromuscular junction [16]. In addition, a few 
hours of totally controlled MV (without any spontaneous 
breathing cycles) promotes decreases of diaphragmatic 
contractile force both in vitro and in vivo [10,16-25]. 
Endurance, as deﬁ  ned by the capacity to maintain con-
trac  tile force when facing an inspiratory resistive load, is 
also signiﬁ  cantly impaired [10,17].
In addition to decreased diaphragmatic force, several 
histological and biochemical modiﬁ   cations have been 
reported in the diaphragms of animals with VIDD. 
Among the most prominent changes is muscle ﬁ  ber 
atrophy [17,19,21,22,25], which is the consequence of 
decreased protein synthesis [26,27] as well as increased 
proteolysis [27-31]. Muscle ﬁ   ber remodeling [25] and 
muscle ﬁ  ber injury are also observed [9,24,31,32]. Several 
of these histological and biochemical changes have been 
linked to an increased level of oxidative stress in the 
diaphragm, which can be observed by 6 hours after MV 
initiation in rats [33] and after 72 hours in piglets [20]. 
Interestingly, the cellular targets of diaphragmatic protein 
oxidation may involve elements of the contractile 
machinery, such as myosin and actin [33]. Proteolysis by 
the calpain (calcium-dependent proteases) [34] and 
caspase systems has been reported to be involved in 
sarcomeric protein breakdown [35] by cleaving and 
disassembling myoﬁ  lament proteins, which can then be 
more readily processed and degraded by the ubiquitin-
proteasome system [36]. Th   ese same proteolytic systems 
have been shown to be activated in the diaphragm during 
the development of VIDD in animal models [27,29,30].
What do the clinical studies in humans show?
Alterations of diaphragmatic function in mechanically 
ventilated patients
One of the major challenges in determining whether 
VIDD occurs in humans is the diﬃ   culty of accurately 
evaluating respiratory muscle function in critically ill 
patients undergoing MV. Th  e American Th  oracic and 
European Respiratory Societies have extensively reviewed 
the methodologies for respiratory muscle evaluation in 
patients [37], and we will only brieﬂ  y summarize tests 
that can be easily applied in the ICU. Measurements of 
maximum inspiratory pressure (Pi,max) are relatively 
easy to perform, but a low value often reﬂ  ects  a 
submaximal eﬀ  ort due to poor patient coordination or 
cooperation rather than true respiratory muscle weak-
ness. Respiratory frequency and tidal volume are also 
easily monitored, and a rapid shallow breathing pattern is 
associated with weaning failure [38], but it is non-speciﬁ  c 
and does not necessarily indicate respiratory muscle 
dysfunction. To overcome the lack of speciﬁ  city of the 
above tests, measurements of transdiaphragmatic 
pressure (Pdi) can be performed in ICU patients. Th  is 
requires simultaneous recordings of esophageal (Pes) and 
gastric (Pga) pressures, with Pdi thus being determined 
as the pressure diﬀ  erence across the diaphragm.
To avoid the diﬃ     culties in interpretation of Pdi 
measure  ments related to variable levels of patient co-
operation, bilateral phrenic nerve stimulation can be per-
formed. As initially described by the team of Similowski 
and colleagues [39], this is well tolerated by most patients 
when using transcervical magnetic (as opposed to 
electrical) stimulation of the phrenic nerves. Using this 
method, Laghi and colleagues [40] measured Pdi before 
and after a weaning trial, and compared the values in 
critically ill patients with weaning success versus failure. 
Twitch Pdi values revealed considerable diaphragmatic 
weakness in almost all ventilated patients, but the study 
suggested that weaning failure was not accompanied by 
low-frequency fatigue of the diaphragm. A high preva-
lence of diaphragmatic weakness, as determined by 
magnetic stimulation of the phrenic nerves, was also 
reported by Watson and colleagues [41] in a population 
of 33 critically ill patients. Recently, Hermans and 
colleagues [11] assessed diaphragmatic force production 
in 25 mechanically ventilated ICU patients using cervical 
magnetic stimulation of the phrenic nerves in a pros-
pective study performed at a single center. Seven of the 
patients were evaluated more than once during their ICU 
stay. Th   e authors reported that values obtained with the 
phrenic nerve stimulation technique were reproducible, 
and that a longer duration of MV was associated with 
more severe diaphragmatic force loss. Th  ey also found 
that diaphragmatic force impairment was correlated with 
the amount of sedation received. However, the authors 
were unable to determine whether sedative use is an 
independent risk factor for diaphragmatic weakness in 
mechanically ventilated patients, or simply a marker of 
more prolonged periods of MV.
Th  e magnitude of the negative deﬂ  ection in tracheal 
pressure during twitch stimulation of the phrenic nerves 
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[42], and has the major advantage of not requiring the 
placement of esophageal and gastric balloon catheters. 
Watson and colleagues [41] ﬁ  rst described the feasibility 
and the reproducibility of using twitch tracheal airway 
pressure (TwPtr) in this manner in intubated ICU 
patients. In our ICU, we also measure TwPtr using 
bilateral, supramaximal transcervical magnetic stimu  la-
tion of the phrenic nerves in patients with unexplained 
weaning failure as part of our routine clinical care. In 
some cases, sedation is necessary to achieve adequate 
patient relaxation during the airway occlusion procedure. 
In addition, when using TwPtr to evaluate changes in 
diaphragmatic force-generating capacity over time, it is 
important to ensure that respiratory mechanics and end 
expiratory lung volume remain relatively stable during 
the measurement period. In a recently published study 
from our group [13], we performed serial measurements 
of TwPtr in critically ill patients who were ventilated for 
approximately one week. TwPtr decreased progressively 
during the period of MV, with a mean reduction of 
32  ±  6% at 6 days. In summary, the human studies 
published to date are consistent in showing that a major 
degree of diaphragmatic weakness is frequently present 
in mechanically ventilated ICU patients. Furthermore, 
the magnitude of diaphragmatic weakness appears to be 
directly correlated with the duration of MV.
Alterations of diaphragmatic structure and biochemistry in 
mechanically ventilated patients
To better understand the mechanisms involved in the 
diaphragmatic weakness reported in critically ill patients 
during MV, diaphragmatic biopsies from mechanically 
ventilated patients are required. Th  e  ﬁ  rst study to obtain 
such tissue samples [43], published in the late 1980s, was 
a post-mortem analysis of neonates, in which diﬀ  use 
diaphragmatic muscle ﬁ  ber atrophy was found in patients 
who received ventilatory assistance for 12 days or more 
immediately before death. Such changes were not present 
in extradiaphragmatic muscles from the same patients or 
diaphragms of infants ventilated for 7 days or less [43].
Another strategy that has been used to study the 
diaphragms of mechanically ventilated patients is to obtain 
the diaphragmatic tissue samples from brain-dead organ 
donors at the time of organ procurement. In comparison 
to other ICU patients, organ donors are often relatively 
free of the confounding eﬀ  ects of multiple organ system 
failure, and these patients also undergo an evaluation to 
rule out sepsis prior to organ donation. In a landmark 
study, Levine and colleagues [15] evaluated diaphragm 
biopsy specimens from 14 adult brain-dead organ donors 
who had undergone MV for variable periods of time (18 to 
69 hours) prior to organ harvest, and compared them to 
specimens obtained from eight control patients who were 
undergoing thoracic surgery for benign lesions or localized 
lung cancer (MV for 2 to 3 hours). Th   e authors reported a 
marked atrophy of both slow- and fast-twitch ﬁ  bers in the 
diaphragms of the MV group compared to the controls, 
whereas no such diﬀ   er  ences were observed in the 
pectoralis muscle. Muscle ﬁ  ber atrophy in the diaphragms 
of patients in the MV group was associated with signs of 
increased oxidative stress (decreased levels of glutathione, 
an antioxidant molecule) and an increase in muscle 
proteolysis bio  markers (caspase-3 and the E3 ubiquitin 
ligases atrogin-1 and MuRF-1).
Using a similar experimental paradigm, Hussain and 
colleagues [12] compared diaphragms from nine brain-
dead organ donors (MV for 15 to 276 hours) and nine 
control patients (lung surgery, MV for 2 to 4 hours). 
Th   ese authors directly demonstrated that prolonged MV 
is associated with increased oxidative stress in the dia-
phragm, as indicated by oxidative modiﬁ  cations  to 
diaphragmatic proteins. In addition to conﬁ  rming  the 
increase in E3 ubiquitin ligases, this paper also reported 
an upregulation of the autophagic system in the 
mechanically ventilated diaphragm. Autophagy (literally 
‘self-eating’) is a catabolic pathway characterized by the 
formation of vesicles (autophagosomes) that engulf cyto-
plasmic organelles and proteins, and then fuse with 
lysosomes that degrade their contents. Th   is process is a 
major regulated mechanism for degrading long-lived 
proteins and the only known pathway for degrading 
organelles. It occurs at low basal levels to perform 
homeostatic functions, but can be rapidly upregulated 
when cells need to generate energy. In their article, 
Hussain and colleagues [12] demonstrated that prolonged 
MV triggers autophagy, and this was associated with an 
upregulation of the transcription factor FOXO-1. Impor-
tantly, these changes were relatively speciﬁ   c to the 
diaphragm and not observed to the same degree in the 
control limb muscle (quadriceps) from the same patients. 
Th  erefore, the authors concluded that MV itself likely 
activates diaphragm autophagy via oxidative stress and 
induction of FOXO-1, thus contributing to the develop-
ment of diaphragm muscle ﬁ  ber atrophy and dysfunction.
Levine and colleagues [14] also examined several 
indices of the ubiquitin-proteasome and Akt-FOXO 
atrophy pathways, as well as the content of contractile 
proteins, in diaphragms of 18 brain-dead organ donors 
(MV for 18 to 72 hours) and 11 short-term (lung surgery, 
MV for 2 to 4 hours) ventilated patients. Th  ey found 
similar results to Hussain and colleagues [12] regarding 
the changes in these atrophy biomarkers, and also reported 
that these modiﬁ   cations were signiﬁ  cantly  correlated 
with the duration of MV. Once again, there were no signi-
ﬁ  cant diﬀ  erences between the MV and control groups in 
the reference control muscle (pectoralis) obtained from 
the same subjects [14].
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chemical evaluation of diaphragmatic biopsies obtained 
from 15 brain-dead organ donors (MV for 24 to 249 
hours) and 10 control patients who underwent thoracic 
surgery for stage 1A lung cancers (MV for 2 to 3 hours). 
In this study by Jaber and colleagues [13], all subjects 
were required to have undergone MV via an endotracheal 
tube in fully controlled mode, that is, without signiﬁ  cant 
spontaneous breathing eﬀ   orts, during the MV period. 
Diaphragmatic biopsies were analyzed for ultrastructural 
changes, atrophy, and the expression of proteolysis-
related proteins (ubiquitin, NF-kB and calpains). 
Compared to the control group, the long-term MV 
patient diaphragms showed signiﬁ  cantly lower values for 
muscle ﬁ  ber cross-sectional area (that is, atrophy), an 
increase in the global levels of ubiquitinated proteins, 
higher expression of p65 NF-κB, and greater protein 
expression levels of the calpain isoforms (1, 2, and 3) in 
the diaphragm.
A particularly interesting ﬁ  nding in our study was the 
presence of ultrastructural injury in diaphragm muscle 
ﬁ  bers, characterized primarily by disruption of the normal 
myoﬁ  brillar organization [13]. Although this observation 
had been made in the past in animal models [9,24,31,32], 
this is the ﬁ  rst report of this phenomenon in mechanically 
ventilated humans. Ultrastructural injury was observed 
with ﬁ  ve to six times greater frequency in long-term MV 
patients compared to the control group diaphragms [13]. 
In addition, the potential role that the calcium-activated 
calpains might play in this process is especially intriguing, 
given their known role in promoting the degradation of 
structural proteins of the sarcomere [34]. Finally, it 
should be noted that both ultrastructural injury and 
atrophy of diaphragmatic ﬁ   bers in the long-term MV 
group were signiﬁ   cantly correlated with the total 
duration of MV.
To summarize, studies performed on the diaphragms of 
mechanically ventilated ICU patients have largely 
conﬁ   rmed animal model data with respect to the 
structural and biochemical changes that take place in the 
diaphragm during MV. Hence, ﬁ  ndings that are common 
to both the animal and human studies include increased 
oxidative stress, muscle ﬁ  ber atrophy and injury, as well 
as the activation of several major proteolytic pathways 
(ubiquitin-proteasome, caspases, calpains). In addition, 
recently published human data point to an important 
degree of upregulation of the lysosomally mediated 
autophagy pathway in the diaphragm during MV.
Potential therapeutic strategies
Mechanical ventilation approaches
Several animal studies have demonstrated that maintain-
ing spontaneous respiratory eﬀ   orts during mechanical 
ventilation alleviates VIDD at either a functional or 
cellular structure/biochemical level [18,21,44,45]. Th  is 
suggests that clinicians should encourage persistent 
diaphragmatic activity, as long as this is compatible with 
adequate patient comfort and gas exchange. Further work 
is needed to ascertain the optimal level of diaphragmatic 
eﬀ  ort and it is not known whether the speciﬁ  c method of 
promoting diaphragmatic eﬀ  ort during MV (for example, 
spontaneous breathing trials, assist-control, and pressure-
support) has any impact upon the risk of developing 
VIDD. Th  e  eﬀ  ects of standard MV settings, such as tidal 
volume and level of applied positive end-expiratory 
pressure (PEEP), should also be evaluated. In addition, it 
would be interesting to determine whether newer modes 
of mechanical ventilation, such as neurally adjusted 
ventilatory assist (NAVA), adaptive support ventilation 
(ASV), and proportional assist ventilation (PAV), have 
any advantages over the more traditional forms of 
ventilatory assistance. Another possible method for 
ensur  ing adequate levels of muscle activity during MV is 
through the use of daily intermittent electrical stimu-
lation, an approach that has been reported to preserve 
muscle mass in the lower extremities of ICU patients 
[46,47]. In theory, this could also be applied to the 
diaphragm as a preventive strategy for VIDD, and this 
approach deserves further investigation.
Pharmacological approaches
It is important to recognize that even when using partial 
support modes of MV or allowing for intermittent 
periods of spontaneous breathing, animal studies have 
found evidence of persistent oxidative stress [18] as well 
as a residual deﬁ  cit of diaphragmatic force production 
[45,48], suggesting that additional measures beyond 
altering the ventilator settings or mode, such as pharma-
co  logical agents, may also be needed to completely 
prevent VIDD in humans. As discussed earlier, both 
animal and human data indicate that MV is associated 
with an increase in markers of oxidative stress in the 
diaphragm. Furthermore, treatment with an antioxidant 
(the vitamin E analogue Trolox) during MV mitigated 
diaphragmatic proteolysis and also prevented the loss of 
diaphragmatic force in animals [49]. Th  is same anti-
oxidant also attenuated diaphragmatic ﬁ  ber atrophy [50]. 
In one study of critically ill surgical patients, an anti-
oxidant supplement containing vitamins E and C was 
reported to reduce the duration of MV in comparison to 
non-supplemented patients [51].
Animal studies have begun to shed light on the main 
sources of the reactive oxygen species (ROS) generated in 
the diaphragm during MV. NADPH oxidase, which can 
generate superoxide within muscle ﬁ  bers [52], was only 
found to be minimally increased in the mechanically 
ventilated diaphragm [53]. In addition, administration of 
the NADPH oxidase inhibitor apocynin, while beneﬁ  cial 
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eﬀ  ects by upregulating an endogenous calpain inhibitor 
(calpastatin) rather than through a speciﬁ  c antioxidant 
action [26]. Xanthine oxidase, another potential source of 
superoxide, is also upregulated in the diaphragm during 
MV, and its inhibition modestly improved diaphragmatic 
contractility but failed to have an impact upon atrophy 
[54]. Given the above, it appears that mitochondria could 
be the main source of excessive ROS production in the 
diaphragm during MV. In this regard, mitochondria 
isolated from mechanically ventilated rats release 
signiﬁ   cantly more ROS and also exhibit biochemical 
evidence of oxidative damage [36]. Furthermore, abnor-
malities of diaphragmatic mitochondrial respiration have 
been found in several animal species during MV 
[36,55,56]. Th  erefore, future studies should focus their 
attention not only on the use of broad-based antioxidants 
for the prevention or treatment of VIDD, but also upon 
the potential use of mitochondria-targeted forms of 
antioxidant therapy.
Th  ere is good evidence that the calpain, caspase, and 
ubiquitin-proteasome proteolysis pathways all play signi-
ﬁ    cant roles in the development of MV-induced atrophy. 
Th  erefore, these proteolytic systems are also logical 
targets for therapeutic intervention. In animals, a single 
administration of leupeptin (inhibitor of calpain/
cathepsin) at the onset of MV not only blocked atrophy 
but also prevented intrinsic contractile impairment in the 
rat diaphragm [29]. Acute high-dose corticosteroid 
administration was also found to prevent calpain up-
regulation and mitigate VIDD in rats [57], although 
cortico  steroids are unlikely to be a viable treatment for 
VIDD given their association with critical illness myopathy 
[58]. Neuromuscular blocking agents can synergize with 
MV to exacerbate VIDD in animals, with attendant 
increases in activation of the calpain and ubiquitin-
proteasome systems [59,60]. Somewhat surprisingly, in a 
recent multicenter randomized study, Papazian and 
colleagues [61] showed that in patients with severe acute 
respiratory distress syndrome (PaO2/FiO2 < 150 mmHg), 
Figure 1. Mechanistic pathways implicated in the human studies of ventilator-induced diaphragmatic dysfunction in critically ill 
patients. Diaphragmatic inactivity induced by mechanical ventilation is associated with an increased generation of reactive oxygen species (ROS) 
and a downregulation of the Akt pathway. This leads to increased proteolysis in the diaphragm via activation of the caspase, calpain, ubiquitin-
proteasome, and lysosomal-autophagic pathways. In addition, downregulation of the Akt pathway also inhibits protein synthesis (dotted line). 
Collectively, all of the above contribute to atrophy and injury of diaphragmatic muscle fi  bers, resulting in functional impairment of the diaphragm. 
Akt-P, phosphorylated (activated) form of protein kinase B.
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cisatracurium administration actually improved survival 
and increased time oﬀ   the ventilator without increasing 
muscle weakness or delaying weaning from mechanical 
ventilation. Nonetheless, cisatracurium administration, 
although perhaps less deleterious than rocuronium 
[59,60], should still be used with care in patients 
undergoing long-term MV (that is, >48 hours), as the risk 
of VIDD is likely to be increased.
Implications and conclusions
In addition to the areas for research into therapeutic 
interventions mentioned above, in the future it will be 
important to determine the inﬂ  uence upon VIDD of the 
prior state of the diaphragm (for example, if fatigued or 
injured) and other co-morbid conditions that could aﬀ  ect 
diaphragmatic properties. For example, in the dia-
phragms of patients with chronic obstructive pulmonary 
disease, multiple abnormalities have been reported, 
including decreased myosin content, ﬁ  ber injury, atrophy, 
and increased protein oxidation [62,63]. Th  ere is also 
very little information available regarding the interaction 
between VIDD and metabolic stresses commonly found 
in ICU patients, such as hyperglycemia and sepsis. With 
regard to the latter, one study has reported that short-
term MV in rats (4 hours) is actually protective against 
endotoxin-induced diaphragmatic dysfunction [64]. 
Further studies are also needed to evaluate the recovery 
response of the diaphragm from VIDD once spontaneous 
respiratory eﬀ  orts have resumed or after MV has been 
discontinued entirely.
In this review we have attempted to emphasize the key 
features of VIDD that have been ascertained from recent 
studies, with a particular focus on the human data 
(Figure 1). It is important to point out that almost all of 
the available animal model data describing VIDD were 
thus far performed in previously healthy animals. Th  is  is 
obviously very diﬀ  erent from the usual scenario in ICU 
patients, in whom multiple confounding factors (for 
example, previous co-morbidities, diﬀ  erent severities and 
causes of ICU admission, drugs, nutritional status, and so 
on) are generally present and could very well contribute 
to reductions in diaphragmatic function. Indeed, due to 
the presence of these multiple confounding factors, it is 
generally impossible for the practicing clinician to assign 
a deﬁ   nitive diagnosis of VIDD to any given patient. 
Hence, in critically ill humans who undergo long-term 
MV, it is likely that several factors converge with VIDD to 
produce diaphragmatic weakness. Given this fact, the 
similarity of ﬁ  ndings between the animal model data and 
the human studies of mechanically ventilated diaphragms 
is all the more remarkable. As was the case with VILI, the 
integration of information gained from studies of animal 
models and human patients should allow us to develop a 
conceptual framework for understanding the problem of 
VIDD and applying this knowledge to patient 
management.
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